Acimtamig

艾西妥米单抗

Report date: 2024/02/02 17:15:54

Base Information

Drug NameAcimtamig
Drug Alias NameAnti-CD30 anti-CD16A antibody(Affimed Therapeutics)TandAb AFM13(Affimed Therapeutics)CD30/CD16A; CD30/CD16A ICE®(Affimed Therapeutics)AFM-13
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionTumor necrosis factor receptor superfamily member 8 inhibitorsAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsNatural killer cells stimulants +[4] 
TargetsTumor necrosis factor receptor superfamily member 8Low affinity immunoglobulin gamma Fc region receptor III-A
Therapy Area/IndicationsLymphoma, T-Cell, PeripheralMycosis FungoidesLymphoma, Large-Cell, Anaplastic +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPolandTurkey +[10] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesThe University Of Texas MD Anderson Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesAffimed GmbhThe University Of Texas MD Anderson Cancer Center
Inactive CompaniesUniversity Of Cologne
Active IndicationsLymphoma, T-Cell, PeripheralMycosis FungoidesLymphoma, Large-Cell, Anaplastic +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksDrugBank